Reassessing Revvity (RVTY) Valuation After Strong Q4 Results And Weaker Guidance Versus Peers

Governance shifts and fresh shareholder pressure

Revvity (RVTY) is drawing fresh attention after solid Q4 numbers and revenue guidance were followed by a weaker peer comparison, a sharp swing in sentiment, and new governance efforts from both the board and an activist investor.

See our latest analysis for Revvity.

At a share price of $85.94, Revvity is trading well below its recent highs, with a 30 day share price return of a 14.34% decline and a 1 year total shareholder return of a 19.67% decline. This suggests momentum has faded as investors reassess tariff risks and the softer peer comparison on guidance.

If the recent volatility around Revvity has you rethinking your exposure to healthcare technology, it can help to scan for other focused opportunities in the sector using 36 healthcare AI stocks

With Revvity trading at $85.94, a sizeable 1-year total return decline and a stated intrinsic discount of 36.85%, the key question is whether this reflects mispricing or a market that is already discounting future growth.

Most Popular Narrative: 28.1% Undervalued

Revvity's most followed valuation narrative points to a fair value of $119.56, well above the last close at $85.94, framing a clear pricing gap for investors to assess.

Ongoing shift in product mix toward higher margin, software enabled and consumables driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.

Read the complete narrative.

Want to see how a richer software and consumables mix, expanding margins, and rising earnings all tie into that higher fair value? The core assumptions link moderate top line growth, a step up in profitability, and a future earnings multiple usually reserved for stronger quality profiles. Curious which specific revenue and margin pathways underpin that $119.56 figure, and how a higher discount rate still leaves room for upside in the model?

Result: Fair Value of $119.56 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this depends on China policy risks and pressure on academic and government funding not worsening in ways that undercut diagnostics volumes and pricing power.

Find out about the key risks to this Revvity narrative.

Another Take: Multiples Paint a Tougher Picture

The DCF work suggests Revvity is undervalued, but the current P/E of 40.1x tells a different story. It sits well above the fair ratio of 23.8x, the North American Life Sciences average of 31.5x and the peer average of 35.2x, which points to meaningful valuation risk if sentiment cools.

That kind of premium can persist for a while, or it can compress quickly if earnings or guidance disappoint. The real question is whether you think Revvity has done enough to justify paying above both its fair ratio and its peer group.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between risks and rewards, now is a good time to look through the assumptions yourself and decide where you stand, starting with 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If Revvity has sharpened your thinking, now is the moment to broaden your watchlist with a few focused sets of stocks tailored to different goals.

• Target potential bargains by scanning for companies that combine quality fundamentals with attractive pricing using the 53 high quality undervalued stocks.
• Prioritize resilience by reviewing companies screened for strong balance sheets and robust financial footing through the solid balance sheet and fundamentals stocks screener (39 results).
• Spot underfollowed opportunities by checking a screener containing 26 high quality undiscovered gems before attention and liquidity potentially pick up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com